LES (USA & Canada) Annual Meeting to Feature Inside Look at the Supreme Court Decision by Myriad General Counsel and All-Star Executive Panel Debate on Patent Trolls

LES (USA & Canada) Annual Meeting to Feature Inside Look at the Supreme Court Decision by Myriad General Counsel and All-Star Executive Panel Debate on Patent Trolls

<0> for LES (USA & Canada)Media Contact:Lydia Steck, (847) 323-3893 </0>

The U.S. Supreme Court’s June 13 ruling on the patentability of DNA marks just one of many complex issues brewing in the intellectual property (IP) space. From life science to high tech, businesses, government and the courts are scrambling to keep up with issues such as: the implications of the Myriad decision; what makes a patent troll; and what’s next in technology convergence. Global leaders in IP, licensing, and business development will share insights and answers at the Licensing Executives Society (U.S.A. and Canada), Inc., , September 22-25 in Philadelphia, PA.

“We are witnessing the most dynamic period in licensing in decades – the final implementation of the America Invents Act (AIA), groundbreaking precedent from the Supreme Court, and pending legislation all show that technological innovation has a profound affect on markets and society,” said Brian O’Shaughnessy, LES Annual Meeting Chair, and V.P. for Public Policy. “The LES Annual Meeting is by experts for experts with new strategies and tactics, extensive networking, and personal access to global leaders offering perspectives on key issues in our rapidly-evolving profession.”

The meeting will draw presenters and attendees from leading companies, research institutions, government labs and other technology-oriented organizations including: AbbVie Biotech Ventures, Advent, BlackBerry, Boeing, Canon, Celgene, DuPont, FTC, Gilead, IBM, Intel, John Deere, Kimberly-Clark, Merck, Microsoft, NIH, Pacific Northwest National Laboratory, Princeton, Shell Americas, Takeda, USPTO, The Wharton School and others.

The Supreme Court’s Myriad decision will have a profound affect on innovation generally, especially in the biotechnology industry. Myriad’s General Counsel Richard Marsh will discuss the decision’s far-reaching implications, along with lessons learned in bringing the company from concept to reality in a highly-anticipated keynote address.

An all-star panel of IP executives will debate featuring: Robert Heath, Senior Vice President of Corporate Development, RPX Corp.; Richard Rainey, Executive Counsel, IP Litigation, GE; Yoav Roth, Senior Managing Director/ Portfolio Manager, Hudson Bay Capital; Julie Samuels, Staff Attorney and The Mark Cuban Chair to Eliminate Stupid Patents, Electronic Frontier Foundation; Jim Skippen, President & CEO, WiLAN; Erich Spangenberg, Chief Executive Officer, IP Navigation Group; Joff Wild, Editor, IAM Magazine (Moderator); and Timothy Wilson, Senior IP Counsel, SAS Institute.

In addition, Ger Brophy, General Manager, New Product Development for GE Healthcare Medical Diagnostics,will focus on innovation and technological convergence in .

The 9 annual LES Deal of Distinction™ Awards will be presented to the most outstanding IP-based licensing and business deals of the year in four industry sectors: High Technology; Chemicals/Energy/ Environment and Materials; Industry-University-Government Interface and Life Sciences. Company deal teams from two of the award-winning deals will be on hand to present an inside look at their transactions.

Both industry-specific and cross-sector mini-plenary sessions will cover an array of topics including valuation, tackling multi-disciplinary deals, IP in M&A, and how to use licensing in resolution of disputes. In addition, numerous interactive workshops and roundtables will delve into real-world successes, failures, lessons learned and best practices. And, as with every LES meeting, there will be numerous networking opportunities, including a reception at the National Constitution Center.

Register by June 30 to save $200. . Attendees are entitled to receive CLE, CLP and CPE credits.

Suggested Articles

Overall, total hospital admissions dropped as low as 69% of predicted levels in April.

Cigna and MDLive have joined forces to offer virtual wellness exams, hoping to bring new patients into the healthcare system.

​​​​​​Global healthcare funding soared in the third quarter, hitting a new record of $22 billion. Digital health investments also reached new heights.